Andere talen VACY AS Oslo Bors

Aandelen

VACC

NO0010714785

slotkoers Oslo Bors Andere beurzen			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
- ^PTS	-.--%		-.--%	-.--%

14/05	Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024
14/05	Nykode Therapeutics AS rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024	14/05
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	14/05
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	19/04
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	21/03
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	19/03
Transcript : Nykode Therapeutics AS, Q4 2023 Earnings Call, Feb 28, 2024	28/02
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Transcript : Nykode Therapeutics AS Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	11/01
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	14/12
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Transcript : Nykode Therapeutics AS, Q3 2023 Earnings Call, Nov 15, 2023	15/11
Nykode Therapeutics Kicks off Early-stage Trial of Head, Neck Skin Cancer Treatment	29-09-23
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer	29-09-23
Transcript : Nykode Therapeutics AS - Analyst/Investor Day	20-09-23
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research	20-09-23
Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer	05-09-23
Transcript : Nykode Therapeutics AS, Q2 2023 Earnings Call, Aug 23, 2023	23-08-23
Nykode Therapeutics AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen VACY AS Oslo Bors

Aandelen

VACC

NO0010714785

Andere talen

Filters